LUMSDAINE ALFRED purchased $88K of ARDT

LUMSDAINE ALFRED (Chief Financial Officer) purchased 10,000 shares of Ardent Health, Inc. (ARDT) at $8.81 on 2026-06-05.

Original reporting
SEC EDGAR · LUMSDAINE ALFRED
Published Jun 8, 2026, 4:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 4:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDT
Bullish
medium confidence
Mentioned
$ARDT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDTBullishLow
01

Why it matters

The newest information is the CFO’s open-market purchase of 10,000 shares at $8.81 on 2026-06-05, reported via Form 4 on 2026-06-08.

02

Market read

Traders may treat this as a small sentiment input, but it does not replace fundamental catalysts like earnings, guidance, or corporate actions.

03

What to watch

The article provides only the buy details; it does not state whether the CFO’s broader compensation/option activity changed, nor any concurrent company fundamentals.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-08; transaction dated 2026-06-05

Background

The article is an SEC Form 4 insider transaction disclosure for Ardent Health, Inc. (ARDT).

Company-level read

Ticker impact

$ARDTBullishMedium confidence
Context

Ardent Health CFO Lumsdaine Alfred bought 10,000 shares in an open-market transaction on 2026-06-05, per SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional company-specific news.

Evidence & confidence

The filing is a primary insider transaction (Form 4) with a defined size, but no accompanying guidance, deal, or operational update is disclosed in the article.

Market effects

No sector-level read-through; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; without a 10b5-1 plan, it still may reflect diversification or personal liquidity needs rather than a strong forward view.

Key entities

  • Ardent Health, Inc.

    Company whose CFO filed the insider transaction (Form 4).

  • LUMSDAINE ALFRED

    Chief Financial Officer who purchased 10,000 shares of ARDT.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDTMed

BofA raises Ardent Health stock price target on acquisition upside

BofA Securities raised its price target on Ardent Health Partners (ARDT) to $14 from $12, citing the company's acquisition of Boone Health. The stock trades at $17.68, near its 52-week high. BofA expects the deal to add $5M-$10M in EBITDA in the first year, growing to $30M-$40M by the third year. Ardent reported Q3 2026 earnings of $0.31 per share, beating estimates. Mizuho also raised its target to $21, maintaining an Outperform rating.

$ARDTMed

What Ardent Health (ARDT) Said on Its Q3 Earnings Call

Ardent Health (ARDT) reported Q3 earnings, highlighting a 9% increase in urgent care visits and a 400 basis point decline in physician referral leakage. Labor costs fell 4.3% YoY, and the company plans to sell a Kansas hospital for 11x EBITDA. Ardent generated $122M in Q3 operating cash flow and lowered its 2026 capital expenditure guidance. The company remains 85% contracted for 2027 and 75% for 2028, with negotiations described as contentious.

$ARDTHighAI 8/10

Ardent Health (ARDT) Q3 2026 Earnings Call Transcript

Ardent Health (ARDT) reported Q3 2026 adjusted EBITDA of $138M, up 1.5% from prior guidance. Revenue was $1.62B, with adjusted admissions up 2.9%. The company plans to divest a Kansas hospital at 11x EBITDA, enhancing margins by 40bps. Ardent's IMPACT program aims for $70M in savings this year, and it raised its EBITDA guidance midpoint by 1.5%.